Agile Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
11.90
12.60
18.00
19.00
23.00
23
Gross Income
11.90
12.60
18.00
19.00
23.00
23
SG&A Expense
12,716.50
18,502.70
33,071.00
29,702.00
26,788.00
18,493
EBIT
12,728.40
18,515.20
-
-
26,811.00
18,516
Unusual Expense
81.00
348.40
1,146.00
234.00
143.00
990
Interest Expense
1,512.90
1,565.70
2,077.00
2,446.00
1,918.00
1,116
Pretax Income
14,320.60
19,730.00
36,307.00
31,816.00
28,304.00
20,256
Income Tax
-
3,652.50
5,972.00
3,075.00
-
477
Consolidated Net Income
14,320.60
16,077.50
30,335.00
28,741.00
28,304.00
19,779
Net Income
14,320.60
16,077.50
30,335.00
28,741.00
28,304.00
19,779
Net Income After Extraordinaries
14,320.60
16,077.50
30,335.00
28,741.00
28,304.00
19,779
Net Income Available to Common
14,320.60
16,077.50
30,335.00
28,741.00
28,304.00
19,779
EPS (Basic)
289.39
1.41
1.38
1.02
0.91
0.58
Basic Shares Outstanding
8,992.10
11,395.00
22,017.20
28,273.30
30,940.80
34,315.90
EPS (Diluted)
1.59
1.41
1.38
1.02
0.91
0.58
Diluted Shares Outstanding
8,992.10
11,395.00
22,017.20
28,273.30
30,940.80
34,315.90
EBITDA
12,716.50
18,502.70
33,071.00
29,702.00
26,788.00
18,493
Non-Operating Interest Income
1.70
2.60
5.00
117.00
282.00
366
About Agile Therapeutics
View Profile
